The Functional Requirement for CD69 in Establishment of Resident Memory CD8 + T Cells Varies with Tissue Location. by Walsh, Daniel
 
 
 
 
 
 
 
 
The Functional Requirement for CD69 in Establishment of Resident 
Memory CD8 + T Cells Varies with Tissue Location. 
 
 
A DISSERTATION 
SUBMITTED TO THEFACULTY OF THE GRADUATE SCHOOL 
UNIVERSITY OF MINNESOTA 
BY 
 
 
Daniel Walsh 
 
 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
 
Stephen C. Jameson (Advisor) 
 
 
July 2019 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Daniel Walsh 2019 
All Rights Reserved
 i 
Acknowledgments  
Works of science are always a collaboration, and this one is no exception. 
There are many people who had a hand in this research, and in my development 
as a scientist. Firstly, I’d like to thank my family. My parents, for instilling a love of 
science in me, for the proofreading, phone calls, career advice, and their 
unwavering support throughout the course of my thesis. I’d like to thank my 
sisters for cheering me up when I was stressed and generally for putting up with 
me. I want to thank all of the Minnesota Walshes for so graciously welcoming me 
when I first moved here and for making sure I survived the winter. I also have to 
thank the rest of my family for all of their support. Finally, I’d like to thank my 
partner Xin for her incredible support, for staying up late to make sure I got home 
safe, for bringing me food when I had to run flow late at night, for baking me 
chocolate muffins every week, for encouraging me to improve myself, for helping 
me try new things, for putting up with my squeaky exercise bikes, for being such 
a loving partner, and for even taking the time to make one of the model figures 
(Figure 3.8) presented in this thesis. You’ve improved me in so many ways, and I 
can’t wait to see what’s next. 
None of this work would have been possible without peanut butter 
(chocolate and regular), blue capped FACs tubes, all of the Pusheens, three 
different exercise bikes, espresso, Coke Zero, flavored sparkling water, the 5th 
Street pedestrian bridge, LCMV-Armstrong, CD69, and all of the friends and 
colleagues who have supported and helped me over the years. 
 I also want to thank my previous scientific mentors. Apart from organizing 
the plasmid library in my mother’s lab (poorly) and cleaning her lab fridge, the 
first lab job I had was with Dr. Mark Kaplan. Working in his lab to study asthma 
helped me develop a better understanding of a medical condition that I have, and 
set me on the path to graduate school. For Dr. Kaplan’s support and mentorship 
that has continued to this day, I am eternally grateful. I’d also like to thank Dr. 
Ana Serezani for her mentorship and guidance during my time in the Kaplan lab. 
 ii 
During the school year I worked in the lab of Dr. Roger Innes studying the plant 
immune system. I am thankful to Dr. Innes for giving me the opportunity to work 
in the lab and my mentor, Thomas Redditt, for his patient guidance.  
Of course I also have to thank the members of the Center for Immunology, 
the MICaB program, and the Jamequist lab. This has been an incredible 
environment to work in for the past five years. I consider myself incredibly lucky 
to have had the opportunity to complete my PhD here. To the members of the 
Jamequist lab (past and present), thank you for the insightful scientific 
discussions, camaraderie, and for being such good friends. Your thoughtful 
criticisms and generosity with your time has been instrumental in my success. In 
particular, Drs. Henrique Borges da Silva, Changwei Peng, Katharine Block, 
Elise Breed, Kristina Burrack, Thera Lee, Kristin Renkema, Roland Ruscher, 
Haiguang Wang, and Kelsey Wanhainen who all contributed directly by helping 
with experiments. I also need to thank Dr. Sara Hamilton Hart for her help with 
experiments immediately after I joined the lab, and Drs. Lalit Beura and Elizabeth 
Steinert of the Masopust lab for their help with experiments. I’d also like to thank 
my thesis committee for their constructive criticism, encouragement, and support 
for my career, Drs. David Masopust, Bryce Binstadt, Ryan Langlois, and 
Christopher Pennell.  
Finally, I have to thank my mentor, Dr. Stephen Jameson. Thank you for 
being a consistent thoughtful presence, for never getting sick of my silly 
questions, for supporting my alternative career path, for your incredible scientific 
insights, for promoting a healthy work life balance in the lab, for fostering an 
incredible training environment (both in the lab and as the DGS of MICaB), for 
personally preparing me for my preliminary exam, for the contemplative weekly 
meetings, for investing in me, and for helping me to improve scientifically, 
professionally, and as a person. The past five years in your lab have without a 
doubt been the best five years of my life, and I know that I’ll look back on them 
fondly.  
 iii 
Abstract 
Recent studies have characterized populations of memory CD8+ T cells 
that do not recirculate through the blood but are instead retained in non-lymphoid 
tissues. Such resident memory CD8+ T cells (TRM) are critical for pathogen 
control at barrier sites. Identifying TRM and defining the basis for their tissue 
residency is therefore of considerable importance for understanding protective 
immunity and improved vaccine design. Expression of the molecule CD69 is 
widely used as a definitive marker for TRM, yet it is unclear whether CD69 is 
universally required for producing or retaining TRM. Using multiple mouse models 
of acute immunization, we found that the functional requirement for CD69 was 
highly variable depending on the tissue examined, playing no detectable role in 
generation of TRM at some sites (such as the small intestine), while CD69 was 
critical for establishing resident cells in the kidney. Likewise, forced expression of 
CD69 (but not expression of a CD69 mutant unable to bind the egress factor 
S1PR1) promoted CD8+ TRM generation in the kidney but not in other tissues. 
Our findings indicate that the functional relevance of CD69 in generation and 
maintenance of CD8+ TRM varies considerably, chiefly dependent on the specific 
non-lymphoid tissue studied. Together with previous reports that suggest 
uncoupling of CD69 expression and tissue-residency, these findings prompt 
caution in reliance on CD69 expression as a consistent marker of CD8+ TRM. 
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Chapter 1 
Introduction  
 7 
1.1 Evolutionary Origins of Adaptive Immunity 
Vertebrates evolved under constant threat from invading pathogens and 
with constant exposure to commensal microbes. Prior to the development of 
modern medical technologies, humans were much more susceptible to death 
from infectious disease (1). The immune system evolved in this crucible, where 
exposure to pathogens was often life threatening.  Two functionally distinct 
branches of the immune system operate in concert to help protect organisms 
from pathogenic threats. The innate immune system defends against infection by 
recognizing the symptoms of pathogen invasion, such as cellular damage or 
conserved molecules and structures common among a wide variety of viral or 
bacterial invaders (2). The adaptive immune system complements innate 
immunity by providing a mechanism to “remember” previously encountered 
pathogens, and eliminate them with enhanced and highly specific immunity (3). 
The specificity and immunological memory of adaptive immunity come with a 
price, however.  The formation of an adaptive immune response is slower to get 
started, and until it does, the innate immune system must hold the invaders at 
bay (3). T cells and B cells are the archetypal adaptive immune cells. T and B 
cells have randomly rearranged receptors (the T cell receptor (TCR) and B cell 
receptor (BCR)) and the capacity to form immune memory. T cells can be further 
subdivided into CD4+ and CD8+ subsets, depending on which coreceptor the 
cells have on their surface. 
 
1.2 The Role of CD8+ T Cells 
Cytotoxic CD8+ T cells are one facet of the adaptive immune response.  
CD8+ T cells recognize peptide antigens being presented in the context of an 
MHC class I molecule.  If an activated CD8+ T cell recognizes the antigen being 
presented as foreign, it will engage its cytotoxic programming and kill the affected 
cell.  Host cells could acquire foreign peptides for MHC class I presentation upon 
infection with intracellular microbes, or upon cellular transformation into a 
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potentially cancer-causing tumor cell. Regardless of the reason, a host cell 
containing foreign peptides is presumed to be a threat to the integrity of the host 
organism. Killing the affected host cell is intended to prevent the threat from 
spreading (4, 5).   
Because CD8+ T cells are adaptive immune cells their activity is highly 
specific. Each CD8+ T cell has a highly specific T cell receptor (TCR), which can 
interact with peptide MHC class I complexes. During T cell development, their 
receptors are randomized, with checks to prevent self-reactive T cells from 
maturing (6).  
 
1.3 The Contribution of CD8+ T cells to Adaptive Immunity 
The narrow specificity of adaptive immune cell receptors is foundational to 
the concept of immunological memory. Prior to exposure to an infectious agent 
the number of CD8+ T cells that recognize any particular foreign antigen, or 
precursor frequency, will be low. However, once CD8+ T cells get activated they 
multiply exponentially generating an overwhelming number of antigen specific 
cells capable of clearing the infection. After the infection is cleared, these same 
cells seed a memory population that is much larger than the naïve population 
was.  If the host is exposed to the same pathogen again, these memory cells will 
be poised to eliminate the threat quickly. This process is immunological memory. 
It would be impossible for the immune system to predict which pathogens the 
host will encounter.  Instead, the immune system is prepared to recognize and 
eliminate anything that is not self (6).  Once the immune system has been 
exposed to an invader, it fortifies its defenses against this particular threat. 
It would not be feasible for the host to maintain the millions of T 
lymphocytes expanded over the course of an immune response, nor is it 
necessary.  As an infection or threat is cleared by the immune system the 
process of contraction greatly reduces the number of antigen specific T cells the 
host needs to maintain. It falls to the remaining memory T cells to survey the 
 9 
entirety of the host. Distinct memory subsets keep watch over distinct tissue 
compartments.  Central memory T cells (TCM) reside in the lymphoid tissues and 
traffic through the blood and lymph.  Effector memory T cells (TEM) circulate 
through some lymphoid tissues (such as the spleen), the blood, and nonlymphoid 
tissues.  Finally, tissue resident memory T cells (TRM) are maintained in the tissue 
(7). Each of T cell subsets contribute, in their own way, to keep the host 
protected from reinfection by previously encountered pathogens. As a note, when 
we subset cells we are sorting cells into distinct boxes as a way of modeling a 
complex system.  Methods like single-cell RNA sequencing have shown us that 
in practice the lines are a bit blurrier (8). Despite this, cell subsets remain an 
important tool that helps us model and understand the immune system (8). 
 
1.4 The Tissue Resident Memory Subset 
Tissue resident memory CD8+ T cells (TRM) are one of the more recently 
characterized subsets but also one of the most important (9). The defining 
characteristic of the TRM subset is their pattern of circulation. These cells reside in 
situ and do not recirculate (7). Canonically, TRM were thought to only live in 
nonlymphoid tissues but recently tissue resident cells have been identified in 
lymphoid tissues (10). The proximity of TRM to the tissue they protect is central to 
their role for host defense. Because TRM are located at potential sites of 
reinfection they are situated to respond immediately. TRM are not dependent on 
the transit of antigen to far-flung lymph nodes by professional antigen presenting 
cells. The function of tissue resident cells regarding reinfection is two-fold. Firstly, 
TRM serve as sentries. Upon reencountering their cognate MHC class I presenting 
the appropriate peptide antigen, TRM produce inflammatory cytokines like IFN-γ. 
IFN-γ produced by TRM drives vascular cell adhesion molecule 1 (VCAM-1) 
mediated recruitment of other immune cells into the inflamed tissue (11). IFN-γ 
also jumpstarts the immune response, inducing an antiviral state by upregulating 
interferon-stimulated genes (ISGs) (12). Secondly, like other CD8+ immune 
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memory subsets, TRM are primed to exert their cytotoxic function and eliminate 
infected cells with precision, using perforin and granzyme B to kill infected cells 
(9, 13).  
The benefits of having TRM in a nonlymphoid tissue are clear, but how do 
cells become TRM? At steady state, naïve CD8+ T cells circulate through the 
blood and secondary lymphoid organs and do not have access to nonlymphoid 
tissue. To understand how they become activated and gain access to these 
tissues, eventually becoming tissue resident, it will be helpful to follow the 
progress of an immune response. 
 
1.5 The Process of Establishing TRM 
Imagine a host’s nonlymphoid tissue (such as the skin, lungs or a mucosal 
barrier) has been infected by a virus. Local innate immune cells need to begin 
producing inflammatory cytokines and chemokines to slow the virus’s progress 
and start the cascade of events that will trigger the adaptive immune response. 
This inflammatory response will partially be driven by nonimmune parenchymal 
cells that sense the presence of infection by detecting hallmarks of an invader. 
For instance the presence of double stranded RNA in mammalian cells indicates 
the presence of a virus, and the RIG-I pathway has evolved to detect it and 
subsequently induce an inflammatory response (14). Likewise, widespread cell 
death and tissue damage signals either the presence of an infection or an 
opportunity for one to take hold (15). Detecting pattern associated molecular 
patterns (PAMPs) or damage associated molecular patterns (DAMPs) alerts the 
innate immune system to the presence of a threat and induces local innate 
immune cells such as innate lymphoid cells (ILCs), macrophages, and dendritic 
cells to begin producing inflammatory cues. Inflammation will help recruit more 
innate immune cells into the infected site to amplify this innate response even 
further. Inflammation also induces an antiviral state, making host cells more likely 
to resist infection. 
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Dendritic cells and macrophages, or antigen presenting cells (APCs) are 
of particular interest here as they serve as an interface between the innate and 
adaptive immune responses. These cell subsets respond to the inflammation and 
are recruited into the tissue to pick up cell debris and sample potential foreign 
antigen at the focus of the inflammatory response. These cells proteolyze 
proteins sampled from phagocytosis, viral infection, or cell transformation to yield 
short peptides that can be presented on the cell surface in the context of an 
MHC-I molecule (16, 17). Carrying their peptide cargo, the dendritic cells migrate 
back to a secondary lymphoid organ, likely the lymph node that drains the 
infected tissue. There they encounter naïve CD8+ T cells (18). 
The adaptive immune response is on the verge of being activated at this 
point. However, the efficiency and lethality with which it acts would be dangerous 
for the host if the immune system were to recognize host cells as foreign. To 
prevent this, in addition to the process of thymic selection, three signals are now 
required for an antigen presenting cell to activate a CD8+ T cell. The first signal 
is transmitted via the T cell receptor, which binds to cognate peptide antigen in 
the context of an MHC molecule on the antigen presenting cell. The second is 
received through the surface receptor CD28, which interacts with either CD80 or 
CD86 on the antigen presenting cell. Finally, the third signal is mediated by 
cytokines such as IL-12 or type I interferons (19, 20). This third signal is partially 
mediated by the actions of activated CD4+ T cells, which interact with antigen 
presenting dendritic cells in a CD40 dependent manner (21). The absence of any 
of these three signals can lead to anergy or cell death instead of a productive 
immune response. 
In order to receive these three signals a naïve CD8+ T cell needs 
prolonged engagement with the antigen presenting cell. This is where CD69 and 
its partner S1PR1 play a role in regulating immunity. S1PR1 is a G-protein-
coupled-receptor that senses a lipid ligand, S1P (22, 23). S1P is primarily 
produced by red blood cells (24, 25), the vascular endothelium (26), and the 
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lymphatic endothelium (27). Immune cells that can sense S1P via expression of 
the receptor S1PR1 will move towards the chemoattractant. S1P is present in a 
gradient, with high concentrations in the blood and lymph, and lower 
concentrations in the parenchyma of lymphoid tissues or nonlymphoid tissues.  
 
If S1PR1 is displayed on the cell surface of a naïve T cell in a lymph node, 
this cell will detect and be drawn to the higher levels of S1P in the draining 
lymphatics, causing the naïve T cell to migrate from lymph node to lymph node or 
back to the circulation (28). However, if there is an active infection, antigen-
specific naïve T cells need to stop and form productive interactions with antigen 
presenting dendritic cells. This is where CD69 steps in. CD69 is a 
transmembrane protein that directly interacts with S1PR1. In CD8+ T cells, CD69 
gets upregulated in response to type I interferons or T cell receptor (TCR) 
signals. In this context, CD69 functions by transiently preventing S1PR1 from 
reaching the cell surface (29). CD69 upregulation is dependent on both RAS (30) 
and PKC (31). CD69 is at its highest protein levels 18-24 hours after stimulation, 
and declines with a half-life of 24 hours (31). The theory is that this gives the 
cells a window of time to interact with antigen bearing dendritic cells without 
being drawn out of the lymph node by the S1P gradient (32). If a strong TCR 
signal is received, this also leads to transcriptional downregulation of S1PR1 (33, 
34). S1PR1 downregulation is mediated by PI3K/AKT suppressing FOX1, which 
was inducing expression of KLF2, which subsequently drove S1PR1 (32). This 
will hold the cell in place for a prolonged period of time ensuring a productive 
interaction.  
A CD8+ T cell that does receive all three of the appropriate signals quickly 
undergoes a dramatic change in its transcriptional programming to adopt an 
effector cell fate. Transcription factors including T-bet and Blimp-1 quickly induce 
the production of effector molecules such as granzyme B and IFN-γ (35). The 
activated cell begins to proliferate rapidly, with cell divisions occurring every 4-6 
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hours (4). This transforms a single naïve precursor cell into a massive clonal 
population of effector cells each capable of recognizing the offending antigen. 
These cells are primed to act, and no longer require costimulatory signals to be 
activated (36). This population undergoes metabolic changes as well, 
dramatically increasing glycolytic and glutaminolytic activity to satisfy the 
energetic demands of the proliferation and cytotoxic functions (37). Over the 
course of the next three days or so, the expanded clonal population of cells 
begins to re-express S1PR1, driving them to leave the lymph node and migrate 
through the blood (33, 38). 
The population of effector CD8+ T cells must now find its way into the site 
of the infection. Upon activation, expression of lymphoid tissue trafficking 
receptors such as L-selectin and CCR7 are downregulated leading the cells to 
leave the lymphoid tissue (35, 39, 40). Conversely, expression of chemokine 
receptors and cell adhesion markers that can draw cells into non-lymphoid 
tissues are upregulated. These include ligands for E- and P-selectin, a4b7, CCR4, 
and CCR10 (41). Different surface molecules have different preferences for 
different nonlymphoid tissue sites (for instance a4b7 canonically draws cells into 
the intestine (42)) with expression of different markers influenced to a degree by 
the site of activation (43). Trafficking is generally promiscuous, however, and 
cytotoxic effector cells are capable of entering a variety of different nonlymphoid 
tissues regardless of where they first saw antigen (41, 44).  
A cytotoxic T cell needs to extravasate, moving from the blood 
compartment into the nonlymphoid tissue to come into contact with infected cells. 
A combination of selectins, chemokines and cell adhesion markers mediate this 
process. Collectively this is referred to as the leukocyte-adhesion cascade (45). 
Activated T cell selectins are expressed by blood vessels in the nonlymphoid 
tissues (and upregulated in the presence of inflammation) (46, 47). An activated 
T cell can bind to these, slowing its progress to a rolling motion in the blood 
vessel. The chemokines expressed by inflamed tissues and presented by 
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endothelial cells induce the effector T cell into a crawling motion along the blood 
vessel. At this point, activated integrins interact with cellular adhesion molecules 
(including ICAM-I and VCAM-I) to induce arrest, and the effector cell can 
translocate through the blood vessel endothelium (45). CD69 potentially plays a 
role in extravasation as well. CD69 binds to myosin 9 and 12, which are both 
present in the blood vessels of inflamed tissues (48, 49). It is not understood 
during which phase of the leukocyte-adhesion cascade CD69-myosin 
interactions occur, but it is likely late in the process as CD69 is not thought to be 
on the surface of effector CD8+ T cells trafficking through the blood. 
After entering the infected tissue effector cells need to come into contact 
with infected cells in order to exert their cytotoxic function. There is some 
evidence that inflammatory chemokines help with this process (50), however, 
their effect is minimal (51) leading to the overall conclusion that contacts with 
infected cells are stochastic (52). After an effector cell comes into direct contact 
with an infected cell, an immunological synapse forms. The formation of the 
synapse is mediated in part by LFA-1-ICAM-1 interactions and partially by 
interactions between the TCR and peptide-MHC-I complex presented on the 
surface of the target cell (53). These interactions cause clustering of engaged 
TCRs and lead to signal transduction events inside the effector CD8+ T cell (54). 
The ultimate consequence of a successful interaction is the targeted release of 
perforin and granzyme B which form pores in and subsequently kills the target 
cell, respectively (55). The Fas ligand pathway is also capable of killing target 
cells (56), and plays a more or less dominant role depending on the model of 
infection (57). Finally, IFN-γ and TNF-a are secreted by the activated CD8+ T 
cell further reinforcing the inflammatory/antiviral cytokine milieu at the site of 
infection (52). Many effector cells start to upregulate canonical markers of TRM 
such as aeb7 integrin (ae is CD103) and CD69 (58). CD103 is upregulated in 
response to tissue signaling including TGF-b (59) and CCR9 (60).  Cells also 
receive residency signals in the form of IL-33 and type I interferons (61). 
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Hopefully, at this point the combined efforts of the innate and adaptive wings of 
the immune system will clear the infection, however, this is not necessary for the 
formation of tissue resident memory cells.  
At the peak of the adaptive immune response more than 10 million antigen 
specific effector cells could be present (62). It is not be sustainable for the host to 
maintain such a large population of cells after sterilizing immunity is achieved, so 
the process of contraction begins. Effector CD8+ cells express a gradient of the 
molecule CD127 (IL-7 receptor) and this inversely correlates with KLRG1 
expression. Most KLRG1hiCD127lo cells are thought to be more terminally 
differentiated effectors (Short Lived Effector Cells) that either die off after the 
immune response or form elements of the TEM compartment. KLRG1loCD127hi 
cells (Memory Precursor Effector Cells) are thought to be the precursors of both 
the TCM and TRM populations (7, 63). Antigen is not required for the eventual 
formation of TRM (61). In some nonlymphoid tissues (NLT), however, its presence 
substantially increases the number of TRM (64). T cell tissue residency may be 
promoted by resident antigen presenting cells. These cells may be a source of 
antigen and survival signals needed for the cells to transition into long term tissue 
residency and may help maintain tissue resident memory cells long term (65). As 
the process of contraction continues tissue signals begin to upregulate a 
transcriptional program of tissue residency. TGF-b plays a particularly important 
role, reducing T-bet and downregulating Eomes in nascent TRM (66),  continuing 
to upregulate CD103 (67), and mediating expression of other P and E-selectin 
ligands (68). Low, but not absent, T-bet expression promotes long term TRM 
maintenance by driving CD122 (IL-15 receptor b) (66). The transcription factor 
KLF2 along with its downstream target S1PR1 are repressed by loss of nuclear 
Foxo1, that is itself induced by cytokine signals transmitted via the PI3K/Akt 
pathway (69). The end result of this is that the absence of S1PR1 signaling 
prevents T cells from leaving the nonlymphoid tissue. As time passes the TRM will 
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begin to adopt a unique transcriptional profile that includes the transcription 
factors Hobit and Blimp1 (70). Runx3 is also known to be important (71). 
Established TRM are maintained by homeostatic cytokines and signals 
produced by their tissue niche, but the signals vary with the nonlymphoid tissue. 
For instance, IL-15 is required for the maintenance of skin TRM (67), but is 
dispensable for TRM in the intestine (72). It has been proposed that TRM are 
maintained in sites of tissue repair in the lungs (73) and skin (74, 75) where they 
interact with antigen presenting cells that maintain an antigen depot (73). It is 
likely that interactions with other immune subsets contribute to the long-term 
maintenance of TRM in even more ways that have yet to be elucidated. 
 
1.6 Common Markers of TRM 
TRM also express integrins that interact with extracellular matrix proteins in 
the tissue providing a mechanical means of retention. CD103 is one of the most 
widely used markers of TRM and is the ae subunit of the integrin aeb7, which binds 
to E-cadherin. Expression of CD103 is associated with residency at epithelial 
S1PR1 KLF2
Recirculation
CD69
Type I Interferons
TCR Signals
FIGURE 1.1 The hypothesized contribution of CD69 to TRM 
The transcription factor KLF2 drives S1PR1 expression, which promotes recirculation. 
CD69 and S1PR1 are mutual antagonists, with CD69 being induced by TCR signals or 
type I interferons. Because of its interaction with S1PR1, CD69’s presence on TRM was 
thought to promote tissue residency and CD69 has become one of the most common 
markers of TRM. 
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barriers (59). CD49a is another commonly used marker of TRM, and is the a1 
component of a1b1, which binds collagen IV (13). Like other antigen experienced 
T cells, TRM also express the glycoprotein CD44 which interacts with the 
extracellular matrix and has a role in cell migration (76). Among all of these 
markers a common thread is direct interactions with extracellular proteins that 
help to anchor tissue resident cells in place. The canonical role of CD69, the final 
widely used marker, is distinct.  
 
1.7 CD69 as a Marker of TRM 
CD69 begins to appear on the surface of effector cells almost immediately 
following entry into nonlymphoid tissues. Its surface expression increases over 
time appearing on most, but not all, TRM at late timepoints (61, 77). CD69 surface 
expression can be driven by TCR signals (78) and type I interferons (79), but it is 
not clear if either of these are responsible for CD69 expression on TRM. CD69 
directly interacts with and antagonizes S1PR1. It has been hypothesized that 
CD69’s contribution to tissue residency is to prevent S1PR1 from reaching the 
cell surface, which prevents cells from leaving the tissue (Fig. 1.1) (80), similar to 
its proposed role during T cell activation in the lymph node as already discussed. 
CD69 and S1PR1 are mutual antagonists, and KLF2 downregulation is required 
for the establishment of tissue resident cells (69, 70). This raises the possibility 
that CD69 expression by tissue resident memory is simply a marker of KLF2low , 
S1PR1low cells, and that CD69’s presence is not actually required. It is also 
possible that CD69 is important for tissue residency in some situations, but not 
others. Context could be provided by the tissue microenvironment and the source 
of the antigen stimulus. The focus of this thesis is to determine the functional 
significance of CD69 expression in a variety of NLT, in the context of varied 
immune responses. 
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Chapter 2 
A Survey of CD69’s Effect on Tissue Residency in Different Contexts 
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2.1 Introduction 
Tissue resident memory CD8+ T cells (CD8+ TRM) play a key role in 
protecting non-lymphoid tissues (NLT) from re-infection (7). Expression of the C-
type lectin CD69, the integrin chains αE (CD103), and α1 (CD49a) are often 
considered definitive markers for typical CD8+ TRM. Because CD103 and CD49a 
are adhesion receptors for the extracellular matrix, their contribution to tissue 
residency in epithelial tissues is predictable. Yet CD8+ TRM in many non-
lymphoid sites do not express CD103 and even in NLT where CD103+ TRM are 
abundant, CD103 expression was not always required for their generation (61), 
suggesting the functional role for CD103 in establishing residency is limited. 
CD49a is similar. It is not universally expressed, even in epithelial barriers where 
CD49a+ TRM are frequently found (13, 80). CD69 by contrast, is expressed by the 
vast majority of TRM in diverse NLT, yet its contribution to residency is unclear. 
Increased cell surface CD69 levels can be driven by either T cell receptor 
stimulation or certain cytokines (79). CD69 binds and antagonizes the cell-
surface expression of G-protein-coupled sphingosine 1-phosphate receptor-1 
(S1PR1) in a cell intrinsic manner (29, 79). S1PR1 signaling promotes trafficking 
towards its lipid ligand, sphingosine 1-phosphate (S1P) which is found in high 
concentrations in the blood and lymph but much lower concentrations in tissues. 
In this way, S1PR1 provides a critical mechanism for T cell egress from lymphoid 
and non-lymphoid sites (81). By inhibiting expression of S1PR1, CD69 can 
therefore impair egress and promote T cell residency (28, 82). In this way, CD69 
expression may promote establishment of resident CD8+ T cells in NLT during 
the acute phase of the immune response. In addition to regulation of S1PR1, 
other functions of CD69 have been defined, (48, 83) though whether these 
impact CD8+ T cell residency programs are not known. As a result of the 
widespread expression of CD69 on CD8+ TRM and its known effect on S1PR1, 
many consider CD69+ cells (with or without CD103 co-expression) as de facto 
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tissue resident, and this criteria has been adopted in studies of TRM in mice, 
humans and non-human primates (84–86).  
However, the fidelity of CD69 expression as a critical characteristic of 
CD8+ TRM has been called into question. In the context of LCMV infection, some 
definitively tissue resident TRM (as defined by parabiosis studies), fail to express 
CD69 (77). Likewise, several studies in mice and humans showed no increased 
Cd69 gene expression in CD8+ TRM compared to recirculating memory cells 
(even, remarkably, when CD69 protein expression itself was used to separate 
these populations) (70, 85). It is possible, however, that these situations reflect a 
transient requirement for strong CD69 expression in seeding resident CD8+ T 
cells, and that CD69 expression can subsequently decline in established CD8+ 
TRM. Some studies are consistent with such a model (87). Alternatively, CD69 
could be a purely passive marker rather than a functional regulator of tissue-
residency. This hypothesis is based on the fact that mutual antagonism of CD69 
and S1PR1 for cell-surface expression results in CD69’s appearance at the 
plasma membrane of T cells expressing low levels of S1PR1 (33). The 
transcription factor KLF2 promotes S1PR1 expression and both S1PR1 and 
KLF2 are downregulated in CD8+ TRM (69, 70, 85) - this loss of expression is 
functionally important, since sustained expression of KLF2 or S1PR1 blocked 
establishment of CD8+ TRM (69). Hence transcriptional downregulation of S1PR1 
could play a key role in establishing residency versus recirculation, with elevated 
cell surface CD69 expression on TRM simply serving as a marker of S1PR1 low 
cells, rather than constituting an active player in driving tissue residency. 
Still, CD69-mediated inhibition of S1PR1 and transcriptional regulation of 
S1PR1 might both play critical roles in generation of TRM, perhaps operating 
sequentially during TRM establishment and maintenance (87). Alternatively, 
CD69-mediated inhibition of S1PR1 and transcriptional regulation of S1PR1 
could be differentially involved in forming TRM depending on the model or specific 
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NLT studied. As a more definitive test of the mechanistic role played by CD69, 
various groups have examined TRM generation by CD69-deficient (Cd69-/-) CD8+ 
T cells. These studies have yielded mixed results. Some studies indicated that 
Cd69-/- CD8+ T cells were severely disadvantaged in generation of CD8+ TRM 
while other reports found a much more moderate effect or a minimal defect in 
generation of Cd69-/- CD8+ TRM (67, 73, 87, 88). These studies used a variety of 
models but focused on a limited set of NLTs, making it difficult to assess the role 
of CD69 in forming TRM at diverse tissue sites.  
To more broadly examine CD69’s impact on CD8+ T cell residency, we 
explored generation of TRM by Cd69-/- CD8+ T cells in multiple NLT, following the 
response to pathogens that establish tissue-specific or systemic infections, and 
subunit vaccination.  
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2.2 Results 
2.2.1 CD69 Deficiency Does Not Impact CD8+ T Cell Residency in Many 
Non-Lymphoid Tissues  
Previous studies suggested a role for CD69 in generating site-specific TRM 
following local infections (the skin after HSV infection and the lung subsequent to 
influenza infection)(67, 73, 87, 88). Whether there is a requirement for CD69 in 
establishing TRM in multiple NLT following systemic infections was unclear. Since 
TRM have been extensively investigated in the context of acute LCMV infection in 
mice (61, 77), we first used this model. Equal numbers of WT and Cd69-/- P14 
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FIGURE 2.1 CD69 plays a minimal role in promoting tissue residency after an 
LCMV infection 
Animals received a co-adoptive transfer of congenically distinct Cd69-/- and WT P14 
CD8+ T cells. At memory timepoints, lymphocytes were isolated from a variety of 
different nonlymphoid tissues (A). The gating strategy used to identify DbGP33-Tet+, IV-, 
transferred cells (B). IV labeling was performed with CD8a antibodies that competed 
with subsequent non-IV CD8a staining. Graphed is the percent of IV- (C) and IV+ (D) 
transferred cells that were Cd69-/- over the percent WT, isolated from the indicated 
tissues days 30-50 p.i. Error bars show mean ± SD, one tailed t test against the known 
ratio of transferred cells on log10 transformed data. 
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(LCMV gp33 epitope specific transgenic T cells) CD8+ T cells were cotransferred 
into congenically mismatched recipients, which were subsequently infected with 
LCMV Armstrong, and the ratio of the CD69-deficent and sufficient cells was 
determined at various time points in lymphoid and non-lymphoid sites (Fig. 2.1A). 
Animals underwent intravenous antibody labeling prior to the tissue harvest to 
distinguish between cells in the vasculature and the tissue parenchyma (89, 
90)(Fig. 2.1B). Unexpectedly, analysis at memory timepoints (>day 30) showed 
minimal differences in the relative proportions of WT and Cd69-/- P14 cells in the 
parenchyma of many tissue sites, although we observed a 3-5-fold disadvantage 
for Cd69-/- P14 in the kidney and a slightly increased proportion of Cd69-/- CD8+ T 
cells in the parenchymal cells of the lung as well as among cells within the 
circulation (blood and spleen; Fig. 2.1C, vascular-associated cells in NLT; Fig. 
2.1D). Since the magnitude of these changes were relatively mild, data were 
aggregated from individual experiments following normalization to the adoptive 
transfer ratio.  
 
 Previous studies suggested that the functional relevance of CD69 may be 
more substantial during initial establishment of the tissue-resident population (69, 
87, 88), therefore we also examined the relative distribution of WT and Cd69-/- 
P14 at the effector phase (day 7) of the LCMV response. Similar to memory-
phase, there was minimal impact of CD69-deficiency on representation of P14 
cells in the parenchyma of many tissues, although again there was a significant 
underrepresentation of this population in the kidney (Fig. 2.2A). The magnitude of 
the kidney residency defect was maintained from this acute timepoint until late 
memory (Fig. 2.2B). Hence, our data suggest a minimal role for CD69 in 
generating or retaining tissue-resident CD8+ T cells during the response to acute 
LCMV infection.  
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It was important to investigate whether CD69-deficiency impacted CD8+ T 
cell homeostasis or initial activation, since this could potentially offset a 
requirement for CD69 in TRM generation. Previous work showed that CD69 
deficiency has no discernable effect on CD8+ T cell expansion or cytotoxic 
function following activation (91–93). We observed that CD69 deficiency slightly 
altered the phenotype but not the numbers of naïve P14 CD8+ T cells (Fig. 2.3A, 
B), that WT and Cd69-/- P14 populations showed similar “parking” efficiency 
following adoptive transfer into animals that were sacrificed prior to infection (Fig. 
2.3 C) and that expression of activation and memory markers on WT and Cd69-/- 
P14 CD8+ T cells was similar over multiple time points (Fig. 2.3A, D). Finally, it 
was notable that CD69 expression by WT P14 cells in the blood was essentially 
undetectable on day 4 of the response to LCMV (when the cells are auditioning 
for tissue entry (94)), consistent with a negligible impact of CD69-deficiency in 
these studies (Fig 2.4A). 
FIGURE 2.2 CD69’s effect on tissue residency is maintained over time 
Animals received a co-adoptive transfer of congenically distinct Cd69-/- and WT P14 
CD8+ T cells followed by LCMV infection. Graphed is the percent of IV- transferred cells 
that were Cd69-/- over the percent WT, isolated from the indicated tissues days 7 (A) and 
over a time course p.i. (B). Error bars show mean ± SD, one tailed t test against the 
known ratio of transferred cells on log10 transformed data. 
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In addition to acting as cytotoxic effectors, TRM serve as immune sentinels 
at barrier surfaces (95). To test the alarm functions of TRM, we evaluated peptide 
rechallenge via the female reproductive tract (FRT) (11). Animals received a 
cotransfer of WT and Cd69-/- P14s, followed by LCMV infection.  At memory 
timepoints, Cd69-/- P14s were present at slightly reduced frequency in the female 
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FIGURE 2.3 CD69 does not affect the phenotype of CD8+ effectors or TRM 
CD25, CD43, CD44, CD69, CD103, CD122, CD127, KLRG1 on naïve cells, 1, or 5 days 
p.i. with LCMV in the kidney or spleen, where indicated (A). Number DbGP33+ cells 
isolated from the spleens of Cd69-/- or WT animals (B). The normalized ratio (CD69-/-
/CD69 WT) of cells recovered from the spleens of mice that received a co-adoptive 
transfer one day prior with no other treatment (C). Surface expression of CD103 in the 
spleen, kidney, and IEL either 7 or 46 days p.i. with LCMV (D). Error bars show mean ± 
SD, two tailed t test for (B), one tailed t test against the known ratio of transferred cells 
on log10 transformed data for (C). 
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reproductive tract (FRT), similar to what was observed in the kidney (Fig. 2.4B, 
2.2A). To assess the function of the FRT WT and Cd69-/- P14 TRM, a cohort of 
memory-phase animals was transcervically challenged with cognate gp33 
peptide (or PBS as a control) to activate FRT TRM (Fig. 2.4C) and quantified 
Granzyme B, IFN-γ, CD44, CD69, CD25, and PD-1 expression on the P14 
population 12 hours later using flow cytometry (Fig. 2.4D, E). Cd69-/- P14s 
exhibited strong induction of activation markers, IFN-γ production and 
upregulation of the cytolytic molecule Granzyme B, albeit some of these 
responses were modestly altered compared to WT P14 cells in the same site. 
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FIGURE 2.4 CD69 does not impact effector functions of TRM 
The percent of CD69 WT co-transferred cells expressing CD69 (gates set on Cd69-/- 
cells) at the indicated timepoints, in the indicated tissues post LCMV infection (A). 
Animals received a co-adoptive transfer of congenically distinct Cd69-/- and WT P14 
CD8+ T cells followed by LCMV infection. At memory timepoints lymphocytes were 
isolated from the whole female reproductive tract and spleen of mice that did not receive 
additional treatment (B). A similar cohort of animals received transcervical re-challenge 
with gp33 peptide or PBS at memory timepoints with isolation of lymphocytes from the 
FRT 12hrs post treatment (C). Quantified expression of Granzyme B, IFN-γ, CD25, and 
PD-1 (D). Representative expression of Granzyme B, IFN-γ, and CD44 on Cd69-/- or WT 
cells isolated from the FRT of LCMV immune animals transcervically challenged with 
either gp33 peptide or PBS control (E). Error bars show mean ± SD, one tailed t test 
against the known ratio of transferred cells on log10 transformed data for (B), paired two 
tailed t test for (D). 
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Hence our data indicate that, despite reduced frequency of Cd69-/- P14 TRM in the 
FRT, these cells exhibit a potent recall response.  
 
Previous studies, using a distinct Cd69-/- strain, had reported substantial 
defects in generation of skin Cd69-/- TRM following intradermal injection of in vitro 
activated CD8+ T cells (87). Indeed, we found that CD69-deficiency led to a 
substantial reduction in the generation of CD103+ skin TRM following this 
approach (Fig. 2.5A, B). Our findings therefore support earlier conclusions on a 
role for CD69 in controlling CD8+ T cell tissue residency in some assays (87), 
and hence validate the impact of CD69-deficiency in our studies. It is important to 
note, however, that in this model CD69 expression by WT cells is clearly 
detectable at the time of injection (Fig. 2.5C) which contrasts with the low 
expression of CD69 on blood cells following LCMV infection (Fig. 2.4A). Such 
data suggest that intra-dermal studies exaggerate the role of CD69, with respect 
to cell-surface CD69 at the time of NLT entry.  
 
 
 
FIGURE 2.5 Absence of CD69 impairs TRM formation following intradermal 
coadoptive transfer 
Congenically distinct Cd69-/- and WT CD8+ P14 T cells were activated in vitro with 
αCD3/αCD28/Il-2 for 4 days followed by a co-adoptive intradermal transfer into recipient 
animals (A). The normalized ratio of Cd69-/- over WT cells isolated from the indicated 
tissues 9 days after intradermal co-transfer with the ratio of transferred cells indicated by 
the dotted line (B). Expression of CD69 on cells at the time of cotransfer (C), and on 
cells isolated from the skin and the spleen 9 days post transfer (D). Error bars show 
mean ± SD, one tailed t test against the known ratio of transferred cells on log10 
transformed data. 
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2.2.2 The Site of Infection Dictates CD69’s Impact on Tissue Residency 
It was possible that the limited role for CD69 in CD8+ T cell tissue 
residency we observed following LCMV infection (including the reduction in 
kidney Cd69-/- TRM), was unique to the tissue-tropism of that pathogen. Previous 
reports showed that CD69 deficiency impairs tissue residency in the lungs after 
influenza infection (88), and the skin after HSV infection (67, 87), consistent with 
a role for CD69 being contingent on the site of tissue tropic infection. Hence, we 
extended our studies to assess the impact of CD69-deficiency on the response to 
influenza, using a recombinant PR8 strain expressing the gp33 epitope, 
recognized by P14 CD8+ T cells (Fig. 2.6A). In agreement with previous studies 
(73, 88) we found that Cd69-/- P14 TRM were under-represented in the lung 
following influenza infection (Fig. 2.6B). This contrasts with our findings after 
LCMV infection, where Cd69-/- cells were overrepresented among the lung 
parenchymal pool (Fig. 2.1C, 2.2A), although previous studies suggest this 
population is not truly resident (96). However, similar to our findings with LCMV, 
influenza infection resulted in reduced accumulation of Cd69-/- P14 CD8+ T cells 
in the kidney (Fig. 2.6B).  
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FIGURE 2.6 Lack of CD69 impairs TRM formation in the lungs and kidney following 
influenza infection 
Animals received a co-adoptive transfer of congenically distinct CD69-/- and WT CD8+ 
P14 T cells, followed by infection with influenza-gp33 one day later (A). The ratio of co-
transferred, IV- cells isolated from a variety of different tissues between 14 and 21 days 
after infection with influenza-gp33 (B). Surface expression of CD103 in the kidney and 
Lungs 14 days p.i. with influenza-gp33 (C). Error bars show mean ± SD, one tailed t test 
against the known ratio of transferred cells on log10 transformed data. 
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It was possible that the role for CD69 in producing TRM within the kidney 
might relate to the P14 TCR specificity: it has been proposed that P14 T cells 
recognize a self-epitope expressed in the adrenal gland, which is proximate to 
the kidney (97, 98). Also, chronic infections with LCMV tend to persist in the 
kidney, potentially implying preferential tropism for this tissue (99). To address 
this, we extended our data to another TCR transgenic model and another 
pathogen, testing the response of WT and Cd69-/- OT-I TCR transgenic CD8+ T 
cells, following infection with VSV-OVA (Fig. 2.7A). As for the studies with P14 T 
cells, CD69-deficiency resulted in reduced OT-I recruitment to the kidney, but 
there was no substantial affect in other NLTs tissues, including the skin (Fig. 
2.7B, C).  
 
Since unexpected viral tropism or immune clearance mechanisms might 
account for the repeated pattern of CD69-dependency in kidney TRM generation, 
we substituted a peptide vaccination approach. P14 T cells were primed using 
“TriVax” immunization (comprising the LCMV gp33 peptide, poly-I:C and 
agonistic anti-CD40 antibody (100)) (Fig. 2.8A). Similar to the other immunization 
methods, Cd69-/- P14 showed impaired accumulation in the kidney, but not the 
liver and spleen (Fig.2.8B, C).  
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FIGURE 2.7 Absence of CD69 does not impair skin residency after VSV infection 
Animals received a co-adoptive transfer of congenically distinct Cd69-/- and WT CD8+ 
OT1 T cells, followed by infection with VSV-OVA one day later (A). The ratio of co-
transferred, IV- cells isolated from a variety of different tissues 7 days after VSV-OVA 
(B). Surface expression of CD103 in the skin and kidney 7 days p.i. with VSV-OVA (C). 
Error bars show mean ± SD, one tailed t test against the known ratio of transferred cells 
on log10 transformed data. 
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FIGURE 2.8 Pattern of tissue residency following peptide vaccine 
Animals received a co-adoptive transfer of congenically distinct CD69-/- and WT CD8+ 
P14 T cells, followed by administration of the TriVax peptide subunit vaccine one day 
later (A). The ratio of co-transferred, IV- cells isolated from a variety of different tissues 7 
days after TriVax (B). Surface expression of CD103 in the spleen and kidney 7 days 
post TriVax (C). Error bars show mean ± SD, one tailed t test against the known ratio of 
transferred cells on log10 transformed data. 
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2.3 Discussion 
The results presented here are the most comprehensive look at CD69’s 
impact on the establishment and maintenance of TRM to date. Using the 
coadoptive transfer model we investigated CD69’s role in TRM formation under a 
variety of conditions. The most notable finding was that in many situations the 
absence of CD69 did not impair the formation or maintenance of TRM in a variety 
of NLT. In the small intestine intraepithelial (SI-IEL), lamina propria (SI-LP), and 
salivary gland CD69 simply was not required for tissue residency after an LCMV 
infection. These data represented a direct contradiction to the accepted theory of 
TRM development. Quoting from Janeway’s Immunobiology, “In these [epithelial] 
sites, TRM induce CD69, which reduces S1PR expression, thereby promoting 
retention in tissues” (101). These data demonstrated that CD69 was entirely 
dispensable for tissue residency in sites where expression of KLF2 and 
downstream S1PR1 has been shown to be a severe detriment (69). Others in the 
field have acknowledged that CD69’s role may be overstated due to the mild 
impact of CD69 deficiency in some models (80), but a situation where CD69 had 
no effect on residency had yet to be uncovered.  
 
Some previous studies did not or were unable to make use of the ratio of 
WT and CD69-deficient transferred cells as a point of comparison, instead opting 
to use the ratio of cells in the spleen as a reference population (73, 88). We 
consistently observed an advantage for Cd69-/- cells in the spleen, implying that 
previous work may have exaggerated the impact of CD69’s absence in non-
lymphoid sites.  
 
The kidney represents a site where CD69’s absence affected tissue 
residency regardless of the model employed. Our experiments with influenza 
show that local infection is not necessary for CD69 to affect tissue residency. 
Experiments with the TRIVAX peptide vaccine lead to a similar conclusion. 
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Because the TRIVAX vaccine is a peptide vaccine and therefore is unlikely to 
form antibody complexes the TRIVAX experiments also led us to conclude that 
an antigen depot established by antibody complexes cleared in the kidney (102) 
is not responsible for the residency defect universally seen in the kidney. Finally, 
the similar outcome in studies with OT-I T cells preclude the possibility that the 
P14 TCR transgenic model was responsible for the kidney’s proclivity for CD69 
expression. Results with the VSV-OVA model also highlighted the 
unpredictability of CD69’s role in tissue residency. Previous work on CD69 
focused heavily on the skin, with CD69 being important for skin tissue residency 
following a HSV infection or intradermal injection (67, 87).  We repeated the latter 
result, but in the context of a VSV infection, we saw that the absence of CD69 did 
not impair tissue residency in the skin. This leads to an obvious question, what 
part of the context provided by an HSV infection is different from a VSV 
infection? The most obvious answer is the chronic nature of an HSV infection, 
and this is a good candidate for future studies. 
 
Finally, we characterized CD69’s impact on the phenotype of TRM, both in the 
steady state and following in vivo reexposure to antigen. We observed no 
meaningful differences between CD69 deficient and sufficient cells in terms of 
their ability to express effector cytokines and chemokines implying that CD69 
deficient cells are just as capable of exerting the sentinel (11) and effector (9) 
functions attributed to TRM. Taken as a whole, these results strengthen the 
conclusion that CD69 promotes recruitment and retention of resident cells at 
sites of local infection, as well as in the kidney regardless of immunization 
strategy, but that CD69-deficiency has little consequence for the establishment or 
maintenance of TRM at some other tissue sites, such as the SI-IEL, and that, in 
CD8+ TRM, CD69-deficiency has little impact on processes other than 
localization. 
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2.4 Methods 
2.4.1 Mice 
C57BL/6 and B6.SJL mice were purchased from the National Cancer 
Institute. CD69 deficient mice were provided by Dr. Linda Cauley at the 
University of Connecticut (88) and crossed to P14 and OT1 TCR transgenic 
animals, as well as onto the C57BL/6 background. These mice were originally 
derived by Dr. Toshinori Nakayama at the University of Chiba.  
 
2.4.2 Adoptive Transfers 
A mixture of splenocytes containing 5x103 TCR transgenic cells at 
approximately a 1:1 ratio were co-adoptively transferred into recipients. C57BL/6 
or B6.SJL recipients were used depending on the congenic markers of the 
transferred cells.  
 
2.4.3 Pathogens and Infections 
Where applicable, 2x105 lymphocytic choriomeningitis virus (LCMV) strain 
Armstrong was injected intraperitoneally (103). 1x106 Vesicular stomatitis virus 
expressing OVA (VSV-OVA), Indiana strain was injected intravascularly. 5x102 
PR8 Influenza-gp33 (Flu-gp33) was applied intranasally following anesthesia with 
ketamine and xylazine. VSV-OVA (95) and Flu-gp33 (94) were provided by Dr. 
David Masopust at the University of Minnesota. 
 
2.4.4 In Situ Peptide Stimulation of FRT TRM 
At least 30 days post coadoptive transfer followed by LCMV infection 
animals were challenged transcervically with gp33 peptide as in Beura et al 
(104). 12 hours later, lymphocytes were isolated from nonlymphoid tissues and 
analyzed by flow cytometry. 
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2.4.5 TriVax Immunization 
A mixture containing 250µg of gp33 peptide, 100µg of agonist αCD40, and 
50µg of Poly I:C was injected into the tail veins of recipient mice. Protocol 
modified from Cho et al (100). 
 
2.4.6 In Vitro Activation followed by Intradermal Cotransfer 
Splenocytes were isolated from CD69 sufficient and deficient P14 TCR 
transgenics and separately activated in vitro with plate-bound αCD3 and αCD28 
as well as 10ng/ml Il-2 for 72 hours at 37° C. At 48 hours, media was changed, 
and cells were moved to new plates without αCD3 and αCD28. After the 72-hour 
incubation, an approximately 1:1 mixture of cultured cells containing 1x106 total 
cells was made and was intradermally transferred into congenically distinct 
recipient animals. 9 days after the intradermal transfer, animals were euthanized, 
and lymphocytes were isolated from the skin and other tissues.  
 
2.4.7 Isolation of Lymphocytes from Nonlymphoid Tissues 
To differentiate cells in circulation from those in nonlymphoid tissues, mice 
underwent the IV labeling procedure as previously described (90), with a 5 
minute gap between IV antibody injection and euthanasia. Lung, kidney, and 
salivary gland were digested with collagenase I and buffers as previously 
described (69), with the following alterations. Lung was incubated with 
collagenase I and digestion buffer for 60 minutes. Additionally, following 
enzymatic digestion, but prior to Percoll purification all of these tissues were 
ground using a gentleMACS tissue dissociator, using the program “Spleen1” 
twice. Cells were isolated from the liver using the gentleMACS tissue dissociator, 
followed by percoll purification, as in other tissues. Cells were isolated from the 
IEL, LP, spleen, and inguinal lymph nodes as previously described (69). 
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Lymphocytes were isolated from the skin and female reproductive tract as 
described by Beura et al (10). 
 
2.4.8 Statistical Analysis 
Data were analyzed using Graph Pad Prism software (8.1.2) Where 
indicated, one tailed t test compared against the known ratio of transferred cells 
using log10 transformed data. Normalization of results in experiments involving an 
adoptive cotransfer of unmanipulated cells, were performed by dividing each 
individual data point by the known transfer ratio for that experimental repeat. Two 
tailed paired and unpaired t tests were also used where indicated. *P ≤ 0.05, **P 
≤ 0.01, and ***P ≤ 0.001. 
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2.5 Publication and Contributions 
Chapter modified (with permission) from the following published article: 
Walsh, D. A. et al. The Functional Requirement for CD69 in Establishment of 
Resident Memory CD8 + T Cells Varies with Tissue Location. J. Immunol. 
ji1900052 (2019). doi:10.4049/jimmunol.1900052 
Author Contributions: 
DAW, DM, and SCJ designed the experiments. DAW, HBdS, LKB, CP, and SEH 
performed experiments. DAW and SCJ wrote the manuscript with input from all 
authors. 
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Chapter 3 
Developing a New Model of CD69-Mediated Tissue Residency 
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3.1 Introduction 
Our results described in the previous Chapter suggested that CD69’s 
impact on tissue residency was more limited than previously had been thought. 
CD69 sometimes seemed to play a role in tissue residency, albeit a limited one. 
We and others (80) observed that even when CD69 does impact tissue residency 
CD69 expression was not  an absolute requirement, simply an advantage. This 
conclusion was based on the magnitude of the residency defect. Interestingly, 
the magnitude of the defect seems to vary with the site of residency, challenge, 
and source of inflammation. For instance, the defect is larger in the kidney than 
the lungs after an influenza infection. Notably, the magnitude of the defect was 
smaller in the kidney after a VSV infection compared to an LCMV infection. 
Previous studies reported more substantial defects in generation of Cd69-/- TRM 
(67, 87, 88). Notably, a wide range of experimental approaches have been 
employed in these previous studies, including substantial differences in the 
numbers of adoptively transferred CD8+ T cells used to evaluate the role for 
CD69 (67, 73, 87, 88). It is well established that altering the number of naïve 
precursor T cells can affect the behavior of those cells during subsequent 
immune challenge (105, 106). We therefore performed experiments to test the 
effects of a range of precursor frequencies on CD69 mediated tissue residency. 
It was also unclear why and how CD69 was affecting tissue residency. 
CD69 is best known for preventing signaling through the G protein-coupled 
receptor S1PR1 (29). There is evidence that inhibiting S1PR1 reverses the 
effects of CD69 deficiency (87), thus it has been taken for granted that inhibition 
of S1PR1 is the sole mechanism by which CD69 acts to promote tissue 
residency. Recently, however, myosin 9 and 12 have been identified as ligands 
for CD69 (48). Myosin 9/12 form net-like structures in the blood vessel, and 
CD69-myosin interactions have been proposed as part of the leukocyte adhesion 
cascade that helps cells transition from the blood into inflamed nonlymphoid 
tissues (49). These results point to CD69 having two distinct roles in establishing 
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tissue resident cells. We wanted to investigate whether the association of CD69 
with S1PR1 versus other ligands (e.g. myosin 9/12) were more important for 
establishing TRM. Ultimately, the results of our studies indicated that interactions 
with S1PR1 were responsible CD69-mediated tissue residency.  
Apart from being consistently important for kidney residency, there was no 
single thread that explained when and why CD69 could play a role in T cell tissue 
residency. The transcription factor KLF2 drives expression of S1PR1, and its 
downregulation is required for cells to become established as tissue resident 
(69). Downregulation of both KLF2 and S1PR1 is a key aspect of the 
transcriptional profile of TRM (70, 85). Just as CD69 binds to and removes S1PR1 
from the cell surface, high levels of S1PR1 will prevent CD69 from reaching the 
cell surface (69). We developed two models for CD69’s role in establishing TRM. 
In the first model, CD69 gets actively upregulated at some point during or soon 
after tissue entry. It prevents S1PR1 from reaching the cell surface, and thus 
actively promotes tissue residency. The second model frames CD69 as a 
passive marker of TRM rather than an active player in establishing them. In this 
model, KLF2 and S1PR1 get downregulated quickly following tissue entry and 
because S1PR1 is no longer on the cell surface CD69 begins to appear there. 
However, our data described in Chapter 2 suggested that the role of CD69 
seemed to be somewhere between these two extremes. Our previous results 
show that the magnitude of CD69-mediated residency was elastic, and that 
CD69 deficient cells were still capable of (if disadvantaged at) forming TRM. One 
caveat to previous studies on the impact of CD69 deficiency (including the 
studies described in chapter 2) has been the use of intravenous (IV) labeling to 
identify TRM as opposed to the more stringent technique of parabiosis. Parabiosis 
is considered the gold standard for identifying truly tissue resident cells, whereas 
IV labeling can overestimate the number of resident cells (107, 108). To address 
the validity of our models, we made use of parabiosis studies to examine the 
impact of CD69 on tissue residency more closely. We then made use of 
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CRISPR/Cas9 derived CD69 knockouts in KLF2 reporter mice to get a better 
understanding of KLF2 expression by CD69 deficient cells. These results helped 
us refine our model for CD69’s role in establishing and maintaining TRM. 
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3.2 Results 
3.2.1 Naïve CD8+ T cell Precursor Frequency can Alter the Defect in 
Residency  
The number of naïve antigen specific cells present prior to infection, or 
precursor frequency, was the first variable we tested. To test the impact of the 
naïve precursor frequency, we co-transferred Cd69-/- and CD69 WT P14 CD8+ T 
cells of varying precursor number (between 5x102 and 5x105 P14 cells) into naïve 
recipients followed by LCMV infection. Seven days later, lymphocytes from a 
variety of different nonlymphoid tissues were isolated. Increasing the naïve 
5e
2
5e
3
5e
4
5e
5
0.1
1
10
# of Transferred P14 Cells
No
rm
al
iz
ed
 K
O
/W
T
Kidney Spleen IV-Liver
*
***
***
A
5e
2
5e
3
5e
4
5e
5
102
103
104
105
106
107
# of Transferred P14 Cells
# 
of
 D
bG
P3
3 
Ce
lls
5e
2
5e
3
5e
4
5e
5
102
103
104
105
106
# of Transferred P14 Cells
# 
of
 D
bG
P3
3 
Ce
lls
B C
Kidney Liver
5e
2
5e
3
5e
4
5e
5
104
105
106
107
108
# of Transferred P14 Cells
# 
of
 D
bG
P3
3 
Ce
lls
Host
CD69 KO
CD69 WT
D
Kid
ne
y
Liv
er LP IEL
Sp
lee
n I
V-
Sp
lee
n I
V+
0.1
1
10
No
rm
al
iz
ed
 K
O
/W
T
*** ** ***** *** *
5e
2
5e
3
5e
4
5e
5
0.1
1
10
# of Transferred P14 Cells
No
rm
al
iz
ed
 K
O
/W
T
Kidney Spleen IV+Liver
E FSpleen
FIGURE 3.1 The frequency of antigen specific cells present prior to infection 
correlates with the magnitude of the defect in the kidney, but not elsewhere 
A range of precursor cell numbers were co-adoptively transferred into recipient animals 
who were then infected with LCMV. The normalized ratio (Cd69-/-/Cd69 WT) of IV- 
transferred cells in each organ 7 days after infection with LCMV (A). The number of IV- 
cells 7 days p.i. in the kidney (B) and liver (C). The number of IV- and IV+ cells 7 days 
p.i. in the spleen (D). Also shown are endogenous DbGP33-Tet+ cells. Normalized ratio 
of IV- Cd69-/-/WT cells isolated from the indicated tissues 7 days p.i. with LCMV, 
following co-adoptive transfer of 5x105 total cells (E). Normalized ratio of IV+ over Cd69-/- 
over WT cells isolated from the indicated tissues 7 days p.i. with LCMV, following co-
adoptive transfer of between 5x102 and 5x105 cells as indicated on the x axis. Ratio of 
transferred cells indicated by the dotted line (F). ANOVA with multiple comparisons on 
log10 transformed data for (A), one tailed t test against the known ratio of transferred 
cells on log10 transformed data for (E). 
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precursor frequency significantly increased the magnitude of the residency defect 
observed for Cd69-/- P14 CD8+ T cells in the kidney (Fig. 3.1A-D). Adoptive 
transfer doses of 5x102 and 5x103 that lead to engraftment of P14 in the 
physiological range of endogenous gp33/Db specific T cells (106), however, 
revealed less substantial effects of CD69-deficiency. Notably, increasing the 
precursor frequency did not alter the relative representation of Cd69-/- T cells in 
other tissues or in the IV+ fraction (Fig 3.1E, F). These data suggest that use of 
non-physiologically high adoptive transfer studies may artificially exaggerate the 
significance of CD69 on establishing residency, at least in some tissues.  
 
3.2.2 CD69 enhances early recruitment to the kidney 
While we found that CD69 deficiency reduced the frequency of resident 
CD8+ T cells in the kidney at effector and memory phases of the immune 
response, it was not possible to determine whether the role of CD69 was 
primarily in initial recruitment to the site or the result of sustained retention. To 
explore this, we modified a previously described model of early T cell trafficking 
to the kidney (68). Mice received co-adoptive transfers of antigen specific WT 
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FIGURE 3.2 CD69 impairs migration into the kidney within a 16 hour window but 
the magnitude of its impact is reduced 
Cd69-/- and WT P14s were co-adoptively transferred as before, followed by LCMV 
infection. 6 days later, 5 million CD8+ T cells were purified from spleens of infected 
animals by magnetic enrichment and adoptively transferred into infection matched 
recipient animals (A). Graphed is the normalized ratio of IV- cells in the indicated tissues 
16 hours after the secondary co-transfer (B). CD69 expression on cells directly prior to 
secondary co-transfer (C) One tailed t test against the known ratio of transferred cells on 
log10 transformed data for (B). 
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and Cd69-/- P14 CD8+ T cells followed by LCMV infection. Six days post 
infection, we purified CD8+ T cells from the spleens of infected host mice and re-
transferred them into infection matched hosts (Fig. 3.2A, B). Of note, neither 
population expressed CD69 on the cell surface at the time of transfer (Fig 3.2 C). 
In secondary hosts, Cd69-/- cells were disadvantaged at entering and being 
retained in the kidney, though the magnitude of the residency defect was less 
than observed in figure 2.1 (Fig. 3.2B). This indicates that CD69 can act within a 
16-hour window to promote tissue entry and/or short-term retention in the kidney. 
Hence, in keeping with previous models, these data suggest that contributions of 
CD69 to CD8+ T cell tissue residency are primarily reflected in initial recruitment.  
 
3.2.3 Forced CD69 expression enhances residency in some tissues 
Similar to previous reports (67, 73, 87, 88), our studies focused on 
defining the role played by CD69 in tissue residency through analysis of Cd69-/- 
CD8+ T cells. However, an important corollary to this approach is to test whether 
ectopic CD69 expression might promote generation of tissue-resident cells. To 
address this, we performed retroviral transduction of in vitro activated, Cd69-
sufficient P14 cells to force expression of CD69, prior to adoptive transfer and in 
vivo priming with LCMV (Fig. 3.3A). This approach does not lead to substantial 
CD69 overexpression (Fig 3.3B), but rather uncouples Cd69 gene expression 
from normal transcriptional control. Compared to empty vector-transduced cells, 
P14 with forced expression of CD69 were enriched in the kidney (Fig. 3.4A-F). In 
other NLTs, there was often a slight trend towards enrichment of CD69 
transduced cells, but it was minor, and not statistically significant. These data 
illustrate that for some NLT, establishment of CD8+ T cell residency does not 
detectably require CD69 yet enforced CD69 expression can improve generation 
of the resident population. Although significant, enhanced recruitment of Cd69-
vector transduced cells in all tissues was relatively slight, in line with the 
reciprocal effects of CD69-deficiency. The retroviral transduction approach 
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allowed us to address the functional basis by which CD69 can promote residency 
in some tissue sites, through use of Cd69 mutants. While CD69 is a C-type lectin 
and has been proposed to have several ligands, its best-defined interaction is 
with S1PR1, leading to mutual inhibition of cell surface expression. Indeed, 
earlier studies suggested that the role of CD69 in promoting CD8+ T cell tissue 
residency could be mimicked by pharmacological blockade of S1PR1 (87). To 
more specifically define the role of CD69-S1PR1 interactions in controlling CD8+ 
T cell tissue residency, we tested the effect of forced expression of a CD69 
mutant, (6N6-Δ31, called CD69-Δ31 here), which does not interact with S1PR1 
due to a domain swap of the CD69 transmembrane domain, but does not alter 
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FIGURE 3.3 Retroviral transduction to understand the mechanism of CD69 
mediated tissue residency 
P14 CD8+ T cells were activated in vitro with αCD3 and αCD28 for 24 hours followed by 
transduction with retroviral vectors containing either empty vector, CD69, or CD69Δ31, 
which cannot interact with S1PR1. Cells then rested in vitro with Il-2 for 48 hours, 
followed by adoptive transfer into congenically distinct recipients (A). Expression of 
CD69 vs the transduction marker CD90.1 following transduction of CD69 WT or Cd69-/- 
P14 CD8+ T cells. Expression of the transduction marker CD90.1 in empty vector, 
CD69, or CD69Δ31 transduced cells, in either Cd69-/- or WT P14s where indicated in 
vitro (B). Expression of the transduction marker CD90.1 in the kidney 6 d.p. LCMV (C). 
The percentage of IV- transferred cells expressing the transduction marker CD90.1 on 
their cell surface in the spleen, normalized to the percent expressing it in the average of 
the spleens for each experimental repeat (D). ANOVA with multiple comparisons on 
log10 transformed data for (B). 
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the C-type lectin, stalk or intracellular domains of CD69 (29). In contrast with 
cells transduced with vectors encoding WT CD69, P14 transduced with 
retroviruses encoding Cd69-Δ31 failed to show enrichment in any NLTs (Fig. 
3.4A-F). This is consistent with CD69-mediated S1PR1 regulation being the key 
mechanism that mediates enhanced generation of tissue resident cells, although 
alterations in interactions with other CD69 ligands by the Δ31 mutation cannot be 
excluded. Together these results indicate that, like CD69-deficiency, enforced 
expression of CD69 has only a limited effect on generation of tissue-resident 
CD8+ T cells.  
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FIGURE 3.4 CD69 acts primarily via S1PR1 to promote tissue residency in the 
kidney 
In vitro activated P14 cells were transduced retroviral vectors containing either empty 
vector, CD69, or CD69Δ31, which cannot interact with S1PR1. Cells were transferred 
into hosts who were infected with LCMV the next day and nonlymphoid tissues were 
harvested 6 days post LCMV infection. Shown is the percentage of IV- transferred cells 
expressing the transduction marker CD90.1 on their cell surface, normalized to the 
percent expressing it in the average of the spleens for each experimental repeat in the 
lung (A), kidney (B), liver, (C) intestinal epithelium (D) intestinal lamina propria, (E) and 
inguinal lymph nodes (F). ANOVA with multiple comparisons. 
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3.2.4 CD69 deficiency impairs residency and appearance of KLF2low CD8+ 
TRM in the kidney 
 The defining feature of TRM is their maintenance within tissues in the 
absence of recirculation. Parabiosis has been used to differentiate between 
resident memory and effector memory cells that transiently traffic through 
nonlymphoid tissues (69, 77, 104). To stringently assess how CD69 functionally 
impacts tissue residency, we used parabiosis to define the recirculation ability of 
CD69 sufficient and deficient cells in various tissues. Animals received a 
cotransfer of Cd69-/- and WT P14s followed by LCMV infection. At memory 
timepoints, these parabiotic donor mice were surgically conjoined with infection 
matched parabiotic recipients that had not received P14 cells. At least 30 days 
later, the percent transferred cells in the blood (Fig 3.5A) and spleen (Fig 3.5B,C) 
was similar in donor and recipient parabionts. We used a formula adapted from 
Steinert et al. (77) to quantify the percent of Cd69-/- or WT cells that were tissue 
Pa
rab
ion
t R
ec
ipi
en
t
Pa
rab
ion
t D
on
or
0
5
10
15
%
Tr
an
sf
er
re
d 
of
 C
D8
+
in
 B
lo
od
NS
Pa
rab
ion
t R
ec
ipi
en
t
Pa
rab
ion
t D
on
or
0.0
0.5
1.0
1.5
2.0
2.5
%
CD
69
 W
T 
of
 C
D8
+
in
 S
pl
ee
n
NS
Pa
rab
ion
t R
ec
ipi
en
t
Pa
rab
ion
t D
on
or
0
2
4
6
8
10
%
CD
69
 K
O
 o
f C
D8
+
in
 S
pl
ee
n
NS
A B C D
Lung Kidney Liver FRT IEL LP
-50
0
50
100
%
 R
es
id
en
t
WT CD69 -/-
**NS NS NS NS NS
FIGURE 3.5 Parabiosis shows many Cd69-/- cells in the kidney are not TRM 
Animals received a co-adoptive transfer of congenically distinct Cd69-/- and WT P14 
CD8+ T cells followed by LCMV infection. At a memory timepoint, these animals were 
surgically conjoined to infection matched animals and left to equilibrate for at least 30 
days. At this point, cells were isolated from each of the indicated tissues with IV+ cells 
excluded from analysis for the nonlymphoid tissues. Shown is the percent of CD8+ T 
cells in the blood that were cotransferred in both the donor and recipient parabionts (A). 
The percent of CD8+ T cells in the spleens of parabiotic donor and recipient animals that 
were WT (B) or Cd69-/- (C). The number of cells in in the donor and recipient parabionts 
were used to calculate the percentage of cells that were tissue resident using methods 
from Steinert et al (D). Error bars show mean ± SEM for (D). Two tailed t test for (A-C) 
ANOVA with multiple comparisons for (D). 
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resident (Fig 3.5D). As expected, the frequency of resident cells detected by flow 
cytometry varied considerably with tissues, ranging from high (in the small 
intestine) to very low (in the lung). The impact of CD69-deficiency on residency 
also differed with tissue site, but in a distinct pattern. Thus, in the SI-IEL and SI-
LP, CD69 sufficient and deficient cells exhibited a similar very high degree of 
residency. Likewise, although few liver cells were resident, this was no different 
for Cd69-/- or WT cells. In the kidney, however, there was a clear and significant 
residency defect for Cd69-/- cells. Furthermore, CD69-/- P14 showed a trend of 
reduced residency in the FRT, although this was not statistically significant. 
Hence, the impact of CD69 deficiency on tissue residency varies considerably 
across non-lymphoid tissues.  
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FIGURE 3.6 Using CRISPR/Cas9 to knockout CD69 gives a similar phenotype to 
germline knockouts 
CRISPR/Cas9 was used to knockout CD69 in KLF2-GFP expressing P14 T cells. 
Animals received a cotransfer of these cells alongside the congenically distinct KLF2-
GFP P14s that used a scramble sgRNA as a control, followed by LCMV infection. 
Expression of KLF2-GFP, CD69, and CD103 on cells that received CD69 sgRNA and 
cells that received scramble sgRNA 7 d.p.i.  in the indicated tissues (A). The ratio of 
recovered CD69 sgRNA/scramble sgRNA receiving cells in the indicated organs 7 d.p.i. 
in the IV- (B) and IV+ (C) one tailed t test against the known ratio of transferred cells on 
log10 transformed data for (B and C). 
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 Reduced KLF2 expression is a functionally relevant feature of tissue 
resident memory CD8+ T cells (69, 70, 85), prompting the question of whether 
the failure of kidney CD69-/- P14 cells to establish residency would correlate with 
altered KLF2 expression. To test this, we used the CRISPR/Cas9 system to 
generate CD69 deficient, KLF2-GFP expressing P14 cells to explore the impact 
of CD69 deficiency on KLF2 expression and to further characterize Cd69-/- cells 
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FIGURE 3.7 CD69-deficiency impairs tissue-residency and appearance of KLF2low 
CD8+ T cells in the kidney 
The ratio of recovered CD69 sgRNA/scramble sgRNA receiving cells in KLF2-GFP hi 
and low cells in the IV- fraction of the indicated organs 7 d.p. LCMV infection is shown in 
(A). The number of cells that received either CD69 or scramble sgRNA, separated by 
KLF2 expression 7 d.p.i. recovered from the kidney (B), intestinal-IEL (C), and spleen 
(D). One tailed t test against the known ratio of transferred cells on log10 transformed 
data for (A). 
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present in the kidney. Activated KLF2-GFP expressing P14s were treated with 
Cas9 and either CD69 sgRNA or scramble controls (109), cotransferred into 
recipient mice and infected with LCMV infection the same day. 7 days post 
infection, lymphocytes were isolated from nonlymphoid tissues. The absence of 
CD69 was confirmed on the surface of cells in nonlymphoid tissues (Fig 3.6A). 
Independent of KLF2-GFP expression the ratio sgCD69/sgCtrl closely mirrored 
the phenotype observed using germline knockouts (Fig 3.6B,C). Interestingly, 
CD69 deficient cells were no longer present at an elevated frequency in the 
spleen. In vitro activated germline knockouts presented with the same phenotype 
upon cotransfer (data not shown). In the spleen and IEL there was no difference 
in KLF2-GFP expression when comparing CD69 sufficient and deficient cells. In 
the kidney the KLF2low population was severely ablated, while the KLF2hi cells 
were intact (Fig 3.6A). This was apparent both by the ratio of cells (Fig 3.7A) and 
by cell numbers (Fig 3.7B-D). These data indicated that the residency defect in 
the kidney was only among KLF2low cells (potentially slated to develop into tissue 
resident memory) and not in the KLF2hi compartment. These data also reinforce 
the notion that reduced KLF2 expression is a defining feature of the tissue 
resident population.  
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3.3 Discussion 
Taken as a whole these experiments resolve several important questions 
in the field and solidify a refined model of CD69-mediated tissue residency for 
CD8+ TRM. The precursor frequency experiments identify an uncontrolled 
variable in the prior work of several groups which may explain the variations in 
the data from different laboratories studying CD69-mediated TRM. The results of 
the short term migration re-transfer assays suggest that CD69 functions in the 
early stages of residency, and can act in a 16 hour window. Previous work 
concluded that CD69’s impact on tissue residency is limited to establishment and 
maintenance during the effector phase of the immune response (87) but our re-
transfer experiments further refined the window in which CD69 was capable of 
acting. Our work is consistent with CD69 promoting residency through S1PR1 
inhibition (29), and not to binding to myosin 9/12 (48), but not dispositive. The 
fact that the magnitude of the residency defect is reduced in this short window of 
time is consistent with S1PR1 inhibition being the more important function 
because S1PR1 would be expected to promote tissue residency over a slightly 
longer window of time. This result strengthens a similar interpretation of our 
retroviral overexpression data, which show that S1PR1 inhibition is solely 
responsible for promoting tissue residency. 
Our results indicate that, contrary to current dogma, CD69 expression 
plays no detectable role in establishment or maintenance of CD8+ TRM in some 
NLT, such as the small intestine intraepithelial (SI-IEL) and lamina propria (SI-
LP) populations while a substantial requirement for CD69 was observed for CD8+ 
TRM generation in the kidney. CD69 expression moderately favored CD8+ TRM 
establishment in the lung following influenza infection and the female 
reproductive tract following LCMV infection. This conclusion was suggested by 
the results of our cotransfer experiments, but the results of the parabiosis and 
CRISPR/Cas9 experiments solidify this conclusion. In complementary studies, 
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forced expression of CD69 enhanced generation of TRM in the kidney but had 
minimal impact on induction of TRM in the other NLT tested. Our studies reveal 
that, despite the near ubiquity of cell-surface CD69 as a feature of CD8+ TRM, its 
functional relevance for establishing or maintaining tissue residency is highly 
variable across distinct non-lymphoid sites. This suggests caution in interpreting 
the presence or absence of CD69 expression as an indication of CD8+ T cell 
tissue-residency.  
The results of the parabiosis and CRISPR/Cas9 experiments were 
particularly striking and led us to reevaluate our model of CD69’s effect on tissue 
residency. Based on the relatively small size of the residency defect observed in 
our cotransfer experiments and the result of our precursor frequency experiments 
we assumed that CD69’s impact on residency was graded. We imagined a model 
where the impact of CD69 fell somewhere between an absolute requirement for 
TRM and not being important at all, and that this impact depended on context, like 
the infectious agent, tissue, or precursor frequency. Instead, the results of our 
parabiosis experiments indicated that measuring the ratio of cotransferred CD69-
WT and Cd69-/- cells substantially underestimated the true magnitude of CD69’s 
impact on tissue residency – but only in cases where it was already clear that 
there was an impact. Specifically, a substantial number of CD69-deficient cells 
were present in the kidney at late memory timepoints but these were not 
functionally tissue resident, making it likely that these are circulating effector 
memory cells. We previously dismissed this possibility because the magnitude of 
the residency defect does not change over time, and we would have expected 
the effector memory population to change over time during contraction. The 
contradiction between these two threads of evidence does seem to indicate that 
this initial assumption was unfounded, and that contraction is similar in the TRM 
and TEM compartments. Further studies will be required to make this conclusion. 
Because loss of KLF2 is associated with tissue residency transcriptionally (69, 
70, 85) and because it indirectly affects CD69 via S1PR1, we hypothesized that 
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KLF2 expression could be used to distinguish the recirculating versus truly 
resident parenchymal cells. This led us to make use of the CRIPSR/Cas9 system 
to ablate Cd69 in KLF2-reporter animals, in an attempt to better characterize this 
putative population. The results of these experiments showed that CD69 
deficiency only impaired tissue residency by KLF2low cells, and indeed, that the 
KLF2hi population was unaffected by the absence of CD69. 
Combined, these insights led us to develop a new model of CD69-
mediated tissue residency (Fig. 3.8) Our results indicate that there are two 
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FIGURE 3.8 A model of CD69-mediated tissue residency 
Nonlymphoid tissues are divided into two classes. The first class includes tissues such 
as the kidney and lung. In these tissues, the presence of CD69 plays a significant role in 
the establishment of TRM by inhibiting S1PR1. The presence of KLF2 expression is 
inferred by lymphocytes auditioning for residency in this class of tissues. A cell 
auditioning for residency in these sites that fails to upregulate CD69 will recirculate. After 
a lymphocyte becomes established in one of these nonlymphoid tissues, it will 
downregulate KLF2 and S1PR1 over time. The second class of tissues is best 
exemplified by the intestinal tissues. In these sites CD69 plays no role in establishing 
TRM. Lymphocytes in these tissues are inferred to adopt a KLF2low S1PR1low 
transcriptional signature prior to or during the process of auditioning for tissue residency. 
The absence of CD69 will not prevent a cell from becoming a TRM in these tissues. 
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different contexts that a cell auditioning to develop into TRM can find itself in. This 
research implies that in tissues like the kidney, KLF2 and downstream S1PR1 
are expressed by many cells fated to become TRM. These cells require CD69 to 
transition into a fully resident population. It is likely that, in its absence, they are 
not maintained in the tissue long enough to receive residency cues from signals 
such as TGF-b (which can drive down expression of KLF2) (69). RNA-seq results 
from other groups show that after this transition period is over, KLF2 and S1PR1 
are downregulated (70, 85). This implies that after a cell becomes established in 
the nonlymphoid tissue, it ceases to rely on CD69. In tissues like the intestine, by 
contrast, our work indicates that KLF2 and S1PR1 are not expressed after cells 
have entered the tissue, or are very quickly repressed. Because of this, tissue 
residency for CD8+ T cells in this tissue appears to be completely independent of 
CD69.  These results suggest that it may be possible to predict the impact of 
CD69-deficency by measuring KLF2 expression by cells auditioning for residency 
under different contexts. Understanding the factors that influence KLF2 
expression in nonlymphoid tissues will be a focus of future studies. 
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3.4 Methods 
3.4.1 Mice 
KLF2-GFP expressing mice (110) were crossed to P14 TCR transgenic 
animals. Animals were maintained under specific-pathogen-free conditions at the 
University of Minnesota. All experimental procedures were approved by the 
institutional animal care and use committee at the University of Minnesota. 
 
3.4.2 Adoptive Transfers 
A mixture of splenocytes containing between 5x102 and 5x105 TCR 
transgenic cells at approximately a 1:1 ratio were co-adoptively transferred into 
recipients. When the precursor frequency is not specified 5x103 TCR transgenic 
cells were used. C57BL/6 or B6.SJL recipients were used depending on the 
congenic markers of the transferred cells.  
 
3.4.3 In Vivo 16 Hour Migration Assay 
A mixture of splenocytes containing 5x103 CD69 sufficient and deficient 
P14 cells at approximately a 1:1 ratio was co-adoptively transferred into 
congenically distinct recipients. The next day, recipients were infected with LCMV 
Armstrong. 6 days post infection, CD8+ T cells were purified via MACS negative 
selection from the spleens of recipients, and 5x106 CD8+ T cells were adoptively 
transferred into infection matched recipient animals. 16 hours after the adoptive 
transfer, the secondary recipients were euthanized, and lymphocytes were 
isolated from the kidney and other tissues. Protocol modified from Ma et al (68). 
 
3.4.4 Retroviral Transduction of P14 Cells 
CD8 T cells were purified by magnetic separation and subsequently 
activated in vitro with plate-bound αCD3 and αCD28 for 24 hours at 37° C. Cell 
cultures were then spinfected for 2 hours at 37° C with viral supernatant 
containing polybrene, βME, and 10ng/ml mIl-2. After spinfection, cells rested for 
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48 hours. Cells were then adoptively transferred into congenically distinct 
recipient animals, who were infected with LCMV Armstrong one day later. 
Adoptive transfers contained 1 million total cells, between 3% and 36% of which 
were transduced with empty vector, CD69, or CD69Δ31 (29) as determined by 
the transduction marker CD90.1. Plasmids encoding these constructs were kindly 
provided by Dr. Jason Cyster (UCSF).  Transduced cells were adoptively 
transferred either alone, or in competition with congenically distinct empty vector 
transduced cells. Protocol modified from Skon et al (69). 
 
3.4.5 Parabiosis 
C57Bl/6J mice were co-transferred with CD69 sufficient and deficient P14 
cells at approximately a 1:1 ratio one day prior to being infected with LCMV. A 
separate group of mice received no transgenic T cells but were infected with 
LCMV to create infection-matched mice. At least 30 days post infection the P14 
transgenic mice were surgically joined along the flank to the infection-matched 
non-P14 bearing mice. Parabiosis surgery was performed as described in Beura 
et al (104). Equilibration of circulating T cell population was confirmed in the 
peripheral blood of conjoined pairs 4 week post-surgery. Parabiotic pairs were 
euthanized and lymphocytes were harvested from indicated tissues 29 or 38 
days post-surgery. The formula from Steinert et al. (77)  was used to calculate 
percent residency, as reported in Fig. 3.5.  
 
3.4.6 CD69 Knockout via CRISPR/Cas9 
KLF2-GFP P14 CD8+ T cells were isolated by magnetic separation and 
activated with plate bound αCD3 and αCD28 (both 5ug/ml) and 100 U/ml rhIl-2 
for 48 hours at 37° C. The next day a 3:1 mixture of sgRNA with Cas9 was made 
and incubated a 20° C for 10 minutes prior to nucleofection using a Lonza 4D-
Nucleofector X Unit (program CM137) per Seki and Rutz (109). Congenically 
distinct cells received sgRNA targeting either CD69 
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(CAUUUUGAGAAGCAUCAUGA and CAUCACGUCCUUAAUAAUAG) or a 
scramble control (GCACUACCAGAGCUAACUCA). Cells were allowed to 
recover for 2 hours at 37°C before being transferred to a 24-well plate with 100 
U/ml rhIl-2 for 2 days. Approximately 40 hours post transfection 5x104 of each 
cell type (CD69/scramble sgRNA) were coadoptively transferred into 
congenically distinct B6 recipient animals, followed by LCMV infection one hour 
later. Aliquots of cells were sequenced 7 days post electroporation and “ICE” 
scores calculated (ice.synthego.com) to determine targeting efficiency. ICE 
scores ranged from 83 to 86. Effective knockout efficiency was determined via 
protein expression in vivo. 
 
3.4.7 Statistical Analysis 
Where applicable, results were analyzed as described in chapter 2. 
Normalization of results in experiments involving transduction with retroviral 
vectors was performed by calculating the displacement of the percent of 
transduced cells in each individual sample from the average percent of cells 
transduced in the spleen. Splenic averages were calculated separately for each 
experimental repeat. The gate defining transduced cells (CD90.1+) was set on 
congenically distinct populations of either endogenous host cells or cotransferred 
empty vector transduced cells where appropriate. Because the gate defining 
transduced cells varied from tissue to tissue, ANOVA with multiple comparisons 
was only used to compare within tissues. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001. 
Error bars show mean ± SD unless otherwise indicated. 
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3.5 Publication and Contributions 
Chapter modified (with permission) from the following published article: 
Walsh, D. A. et al. The Functional Requirement for CD69 in Establishment of 
Resident Memory CD8 + T Cells Varies with Tissue Location. J. Immunol. 
ji1900052 (2019). doi:10.4049/jimmunol.1900052 
Author Contributions: 
DAW, DM, and SCJ designed the experiments. DAW, HBdS, LKB, CP, and SEH 
performed experiments. DAW and SCJ wrote the manuscript with input from all 
authors. 
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Chapter 4 
Conclusion  
 59 
The proposed functional role of CD69 expression as being critical for 
establishment of memory T cell tissue residency has been widely embraced, 
reaching the level of acceptance in immunology textbooks (101). Our data, 
however, argue against such a universal role for CD69. Rather, the functional 
significance of CD69 expression varies considerably with tissue site and 
immunization model. We also found that non-physiological assays, such as direct 
injection of activated CD8+ T cells into NLT and adoptive transfer experiments 
involving high numbers of naïve precursors may exaggerate the impact of CD69 
in at least some tissues sites. Hence, we conclude that a non-redundant 
functional role of CD69 in dictating CD8+ T cell tissue residency is modest or 
absent for several non-lymphoid tissues.  
We confirmed a role for CD69 in generating resident cells in the lung 
following influenza infection, consistent with other studies involving local 
infections (67, 73, 87, 88). These results may suggest that residual antigen 
and/or inflammation localized at the site of infection promotes or sustains a 
CD69-dependent recruitment or retention process. Even so, the impact of CD69-
deficiency in the influenza-infected lung was relatively modest, as has been 
reported previously (73). It is possible that a functional role for CD69 may be 
stronger in situations of chronic infection, and it is notable that the most dramatic 
requirement for CD69 in driving CD8+ T cell residency comes from studies of the 
response to persistent HSV infection in the skin (67), but further studies will be 
required to compare the functional role for CD69 in situations of sustained versus 
transient antigen exposure.  
On the other hand, a substantial impairment in generation of Cd69-/- TRM 
was observed in the kidney regardless of the immunization strategy (including 
use of the TriVax sub-unit vaccine), suggesting that local infection is not the only 
circumstance where CD69 expression guides T cell tissue residency. Indeed, 
CD69-deficiency led to a reduction in the development of a tissue-resident 
population in the kidney (as defined by parabiosis), while CD69-/- CD8+ T cell 
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residency was unimpeded in the SI-IEL and SI-LP pools.  This corresponded with 
defective recruitment of KLF2low CD8+ T cells to the kidney following CD69 
ablation. In previous studies, we showed that reduced expression of KLF2 and its 
transcriptional target S1PR1 was necessary for generation of CD8+ TRM in many 
non-lymphoid sites (69). Hence there are two ways in which S1PR1 protein 
expression might be limited on TRM – one involving loss of S1pr1 transcription 
(typically following loss of KLF2 expression), and the other associated with 
upregulation of CD69 which can impede cell-surface expression of S1PR1 
protein. Although one could imagine that these pathways could operate 
independently, it is noteworthy that in the case of the kidney, where we find a 
clear-cut requirement for CD69 in establishing tissue-residency, CD69-deficiency 
is not compensated by an increased frequency of KLF2low cells.  To the contrary, 
KLF2low cells were virtually absent in the rare Cd69-/- cells from the kidney 
parenchyma.  This might imply that, for the kidney, CD69 induction is a 
necessary pre-requisite for down-regulation of KLF2, as was previously proposed 
for skin TRM (87). For other tissues, such as the SI-IEL, however, it appears that 
KLF2-downregulation is entirely independent of the ability of the TRM precursors 
to express CD69.   
It is unclear why formation of the kidney TRM pool would so consistently 
and substantially depend on CD69 expression. Interestingly, S1PR1 and its 
ligand S1P are important for renal function, including sodium secretion 
(natriuresis) (111–113). Hence, while S1P is degraded in the parenchyma of 
most tissues (28, 82), there may be areas of the kidney that maintain elevated 
levels of S1P. In such a scenario, blocking cell-surface S1PR1 through CD69 
upregulation on circulating T cells, might provide a key advantage to avoid 
responding to S1P in the kidney. While it is of course possible that the 
contribution of CD69 to residency in the kidney is independent of its interactions 
with S1PR1, the fact that the CD69-Δ31 mutant, which retains the entire 
extracellular domain of WT CD69, fails to enhance CD8+ T cell residency in the 
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kidney makes the role for alternative ligands less likely. TCR (32) signal and 
cytokines such as TGF-b (69) are all capable of downregulating expression of 
KLF2. Other groups have established that TCR signals are important for 
establishing TRM, especially in sites like the lungs (96) and skin (64). Likewise, 
the presence of TGF-b receptor on auditioning CD8+ T cells is important for 
establishing TRM (68). These lines of evidence raise the possibility that tissue 
signals (including but not limited to TGF-b and TCR signals) repress KLF2 over 
time as a CD8+ T cell auditions for tissue residency. The presence and relative 
amounts of each of the different factors could be what dictates a requirement for 
CD69. In nonlymphoid tissues with fewer KLF2 repressing signals, CD69 would 
play a larger role. If this is the case, it may be possible to predict the impact of 
CD69 by looking at KLF2 expression on cells auditioning for residency. We would 
predict KLF2 to be expressed at higher levels and/or longer by T cells in the 
kidney, and to be suppressed quickly after tissue entry in the small intestine. This 
tissue specific context could be informed by many different variables. One 
possibility is the tissue parenchyma serving as a source of TRM promoting 
cytokines (114). Likewise, the presence of E- and P-selectins in the blood 
vessels varies with the NLT (45, 46). The context provided by the innate immune 
system remains the most likely candidate, however. There is evidence that 
interactions with innate immune cells serves to maintain TRM (65), and that the 
absence of such cells prevents TRM from ever becoming established in the first 
place (115). It is possible that interactions with innate immune cells shortly after 
entering a nonlymphoid tissue license a cell to become resident. Antigen 
presentation, bystander cytokines, or some mixture of the two could be 
responsible for this. Perhaps the absence of CD69 prevents nascent TRM from 
forming productive interactions with antigen presenting cells immediately after 
entering some nonlymphoid tissues. This hypothesis would predict that innate 
immune subsets would differ between NLTs. Given their role as professional 
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candidates for a difference between, for instance, the kidney and small intestine. 
Alternatively, the localization of innate cells may be distinct in different NLT. 
Regardless of the mechanism, the contribution of innate immune subsets the 
establishment of TRM remains an understudied area, and should be a topic of 
future research. 
Interactions with innate immune system and anatomical quirks of the 
kidney are attractive explanations for CD69’s seemingly random proclivity for 
particular residency contexts. One alternative is that CD69’s role in tissue 
residency is an evolutionary holdover. CD8+ T cells are not the only immune 
subset that are classified as tissue resident. ILCs, macrophages, and γδ T cells 
also have tissue resident subsets (116). In contrast to adaptive immune TRM, 
however, tissue residency in these cells is regulated developmentally. For 
instance, the dendritic epidermal population of γδ T cells is seeded into the skin 
of mice at embryonic days 14-16 and these cells are thought to perform an innate 
like immune function, recognizing keratinocyte stress antigens (117). A recent 
report concluded that CD69 was important for the retention of developmentally 
seeded γδ T cells, and the maintenance of keratinocyte health (118). Likewise, 
CD69 expression by CD4+ T cells mediates improved antibody affinity by 
improving T follicular helper cell function (119) and biases cells towards a T 
regulatory cell fate by simultaneously inhibiting S1PR1 and promoting STAT5 
signaling (120). Apart from these specific examples, CD69 is expressed by a 
wide variety of immune subsets, and is used as an early marker of activation on 
natural killer, B cells, monocytes, neutrophils and eosinophils (121). Interestingly, 
CD69 is differentially regulated by T and B cells, and more strikingly, by mature T 
cells and thymocytes with different promotor elements regulating its expression in 
different cell types (122). CD69’s widespread pattern of expression is consistent 
with it appearing early during the evolution of the immune system. CD69 is 
hypothesized to have diverged from a family of proteins which includes many 
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natural killer cell markers (123). It may be that CD69 expression in some subsets 
is simply vestigial, though this is clearly not the case for all CD8+ TRM. 
Our studies demonstrated that Cd69-/- CD8+ T cells are present at 
elevated frequencies in the spleen (and, in some situations, the blood and lymph 
nodes). The basis for this finding is unclear but may indicate that loss of basal 
CD69 expression promotes S1PR1-mediated recruitment or retention in the 
spleen. There is precedent for altered lymphoid tissue localization of Cd69-/- cells. 
Others have reported that CD69-deficient CD4+ T cells cannot enter the bone 
marrow, and this entry defect prevents them from inducing high affinity antibodies 
produced by bone marrow resident plasma cells (119). It may be that the 
localization of CD69-deficient CD8+ T cells is altered in the spleen or lymphoid 
organs in an analogous fashion, but the techniques we used were not capable of 
resolving this question. Regardless of the mechanism, this result may further 
exaggerate reports of impaired NLT residency by Cd69-/- CD8+ T cells, since 
Cd69-/-/WT ratios in the spleen have often been used as a reference tissue in 
these studies.  
Consistent with other proposed models (67, 87), our data suggest that any 
discernable role for CD69 in regulating CD8+ T cell residency in NLT residency is 
manifest early in the immune response, at least in the models of acute 
infection/immunization studied here. We did not find that effects of CD69-
deficiency became more or less marked when studying tissue-associated cells at 
the effector phase versus TRM at long-term memory time points. Likewise, we 
were able to show that CD69-dependent recruitment to the kidney could be 
measured in short-term (16h) homing assays. Together, these data suggest that 
a functional role of CD69, following acute immune responses, is likely to mediate 
initial recruitment and seeding of the NLT sites (87). Resident cells unable to 
make CD69 did not express higher levels of CD103 to compensate for CD69’s 
absence. This reinforces the idea that CD69 and CD103 function at distinct 
timepoints. In seeming contrast with this, sustained cell-surface CD69 expression 
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is one of the most consistent features of long-term TRM. Loss of S1PR1 
expression (frequently associated with loss of KLF2 expression (69, 103)) may 
lead to cell-surface CD69 derived from basal expression in memory CD8+ T cells. 
Still, one might expect that some CD8+ TRM may extinguish Cd69 gene 
expression during their maintenance in NLT, if it does not play a functional role. 
In fact, there is existing evidence for this idea, since analysis of tissue-resident 
CD8+ T cells by quantitative immunofluorescence and parabiosis indicates that a 
significant fraction of TRM in various sites (pancreas, salivary gland, but also 
kidney) lack expression of CD69 (77). In addition, a meaningful fraction of CD69 
expressing cells in lymphoid tissues recirculate (10). These studies could not 
discern whether CD69 expression was critical for initial seeding to those NLT but 
in conjunction with our findings, it is likely that a significant fraction of T cells that 
do not express CD69 or rely on CD69 for their establishment are indeed resident 
in NLT. Likewise, our studies using forced CD69 expression, following retroviral 
transduction, suggested relatively mild impact on recruitment of cells to NLT. 
Together, such findings suggest considerable caution is warranted in interpreting 
the significance of CD69 expression as an indication of tissue-residency by CD8+ 
T cells in both lymphoid and non-lymphoid tissues. Although there is a growing 
understanding of the unique gene expression characteristics of TRM versus 
recirculating cells, most of these studies used CD69 expression as an essential 
marker for identifying “resident” cells, and hence reinforce reliance on this 
molecule for their analysis. At least in mice, it would be better not to infer 
residency solely from CD69 surface expression. 
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